alexa Why Don’t Immune Checkpoint Inhibitors Work
ISSN: 2572-4126

Journal of Gastrointestinal Cancer and Stromal Tumors
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication

Why Don’t Immune Checkpoint Inhibitors Work in Colorectal Cancer?

Yuequan Shi1, Zifang Zou1 and David Kerr2*

1Clinical college, China Medical University, Liaoning, China

2Radcliffe Department of Medicine, University of Oxford, UK

*Corresponding Author:
David Kerr
Radcliffe Department of Medicine
University of Oxford, UK
Tel: 00447976708535
E-mail: [email protected]

Received date: April 19, 2017; Accepted date: May 03, 2017; Published date: May 13, 2017

Citation: Shi Y, Zou Z, Kerr D (2017) Why Don’t Immune Checkpoint Inhibitors Work in Colorectal Cancer?. J Gastrointest Cancer Stromal Tumor 2:114. doi:10.4172/2572-4126.1000114

Copyright: © 2017 Shi Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

In recent years, immune checkpoint inhibitors have been shown to be effective in treating manifold types of cancer but less robust in colorectal cancer (CRC). While, the subgroup of CRC with microsatellite instability (MSI; also termed as mismatch repair deficient) showed a moderate response to Pembrolizumab in a single arm phase II clinical trial, microsatellite stable (MSS) cancers were unresponsive. Possible mechanisms that affect immune response in colorectal cancer will be reviewed in this article. We will also propose that histone deacetylase (HDAC) inhibition may reverse the immune editing commonly seen in advanced CRC and render them sensitive to immune checkpoint blockade.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords